Independent register of U.S. FDA drug recalls · updated Oct 13, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,543 recalls, newest first.

Class II · Moderate risk

CycloSPORINE Capsules

Failed Impurities/Degradations Specifications; out of specification results for Maximum Unknown Impurities and Total Impurities

Terminated Impurity / degradation Amerisource Health Services NDC 68084-921-25 D-0490-2017
Class II · Moderate risk

Indocin (Indomethacin)

Failed Impurities/Degradation Specifications: Out of specification (OOS) for total impurity and out of trend for known impurity results encountered during stability testing.

Terminated Impurity / degradation G & W Laboratories, Inc. NDC 42211-0102-43 D-0501-2017
Class II · Moderate risk

GlipiZIDE Extended-release tablets

Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.

Terminated Dissolution failure Amerisource Health Services NDC 68084-295-21 D-0520-2017
Class II · Moderate risk

CycloSPORINE Capsules

Failed Impurities/Degradations Specifications; out of specification results for Maximum Unknown Impurities and Total Impurities.

Terminated Impurity / degradation Apotex Inc. NDC 60505-0134-0 D-0475-2017
Class II · Moderate risk

Transderm Scop

Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.

Terminated Labeling / mix-up Sandoz Inc NDC 66758-208-58 D-0481-2017

Recalls by year